COMMUNIQUÉS West-GlobeNewswire

-
CARBIOS se réjouit de l'autorisation du régime d'aide d'État "Économie circulaire" par la Commission européenne
06/02/2025 - 18:30 -
CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme
06/02/2025 - 18:30 -
Lytus Technologies Expands HealthTech Initiatives and Strengthens Growth Trajectory
06/02/2025 - 18:48 -
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
06/02/2025 - 20:07 -
MannKind to Present at Upcoming Investor Conferences
06/02/2025 - 22:05 -
BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
06/02/2025 - 22:05 -
Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
06/02/2025 - 22:05 -
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
06/02/2025 - 22:05 -
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/02/2025 - 22:05 -
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
06/02/2025 - 22:05 -
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
06/02/2025 - 22:06 -
LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025
06/02/2025 - 22:10 -
GENFIT présente le design de ses prochains essais cliniques et rappelle les grandes étapes de développement et données cliniques attendues en 2025
06/02/2025 - 22:10 -
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
06/02/2025 - 22:10 -
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
06/02/2025 - 22:15 -
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
06/02/2025 - 22:15 -
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
06/02/2025 - 22:15 -
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
06/02/2025 - 22:23 -
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
06/02/2025 - 22:30
Pages